蕲蛇酶治疗肥胖2型糖尿病5年追踪疗效观察

目的观察蕲蛇酶对于肥胖的发病早期的2型糖尿病患者的远期疗效。方法BMI≥30、病史不超过2年的2型糖尿病患者32例,给予蕲蛇酶0.75U静滴,1日1次,共10d。在专科医师指导下进行糖尿病饮食和运动,追踪随访期间实验对象每年减体重〉5kg,使体重控制在BMI24-28,观察治疗前和治疗后每年的体重指数（BMI）、空腹血糖（FPG）、空腹胰岛素（FINS）、餐后血糖（FBG）、餐后胰岛素（PINS）、糖化血红蛋白（HbA1c）,治疗前与治疗后第五年检测值进行比较。结果治疗前和治疗后第五年BMI、FPG、FINS、FBG、PINS、HbA1c差异有显著性意义P〈0.01。结论蕲蛇酶治疗肥胖、发病早期的2型糖尿病患者可获得良好的降糖疗效,血糖、HbA1c在5年内持续达标,不引发低血糖,不加重肥胖,达到长期缓解的目标。

Efficacy of 5-year follow-up of acutase in the treatment of obese type 2 diabetic

OBJECTIVE To observe the long-term efficacy of Acutase for early onset obesity in patients with type 2 diabetes. METHODS BMI≥30, a history of not more than 2 years with type 2 diabetes in 32 patients given intravenous Acutase 0.75 units, 1 time/d, a total of 10 days. Under the guidance of specialist physicians in the diabetes diet and exercise, tracking follow-up subjects during the weight reduction a year 5 kg, so that weight control BMI24-28, observed treatment before and after treatment the annual body mass index （BMI）, fasting plasma glucose （FPG）, fasting insulin （FINS）, postprandial blood glucose （FBG）, postprandial insulin （PINS）, glycosy- lated hemoglobin （HbAlc）, and treatment before treatment after five years of test values for compari- son. RESULTS before treatment and after treatment for 5-years BMI, FPG, FINS, FBG, PINS, HbAlc difference was statistically significant （P 〈 0.01）. CONCLUSION Acutase treatment of obesity, early onset type 2 diabetic patients receive a good effect, blood glucose, HbAlc continued compliance within 5 years and not cause low blood sugar, not to aggravate the obese, to achieve long-term mitigation goals.